Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aldicarb. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.32 |
| ▸ | BHMT | Q93088 | 4/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.30 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.30 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.30 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.30 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aldicarb SCHEMBL20568578 | 0.88 | TDP1 (0.64) | TDP1ALDH1A1TSHRHSD17B10GRIK1 | |
| Cystine SCHEMBL14645188 | 0.88 | TDP1 (0.68) | TDP1ALDH1A1TSHRHSD17B10GRIK1 | |
| Aldicarb SCHEMBL10933284 | 0.88 | TDP1 (0.68) | TDP1ALDH1A1TSHRHSD17B10GRIK1 | |
| Aldicarb SCHEMBL8778632 | 0.84 | TDP1 (0.63) | TDP1ALDH1A1TSHRHSD17B10CYP2C19 | |
| Aldicarb SCHEMBL21327721 | 0.84 | TDP1 (0.90) | TDP1ALDH1A1TSHRHSD17B10 | |
| Aldicarb SCHEMBL4061104 | 0.82 | TDP1 (1.00) | TDP1ALDH1A1TSHRHSD17B10 | |
| Aldicarb SCHEMBL9781 | 0.82 | TDP1 (1.00) | TDP1ALDH1A1TSHRHSD17B10 | |
| Aldicarb SCHEMBL7626286 | 0.82 | TDP1 (1.00) | TDP1ALDH1A1TSHRHSD17B10 | |
| Aldicarb SCHEMBL7864399 | 0.82 | TDP1 (1.00) | TDP1ALDH1A1TSHRHSD17B10 | |
| Aldicarb SCHEMBL7864397 | 0.82 | TDP1 (1.00) | TDP1ALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112779303-A | Method for synthesizing orotic acid by biological enzyme method | 华东理工大学 | 2021-05-11 | — | — | CN | claimed |
| EP-4687871-A1 | TOPICAL PALA THERAPY FOR CANCER | The Cleveland Clinic Foundation (US) | 2026-02-11 | — | — | EP | disclosed |
| CN-119286751-B | Genetically engineered bacterium for producing uridine diphosphate glucose, construction method and application thereof | 诸城市浩天药业有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119391619-A | Engineering strain for producing uridine diphosphate, construction method and method for synthesizing rebaudioside M | 诸城市浩天药业有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-119286751-A | Genetically engineered bacterium for producing uridine diphosphate glucose, construction method and application thereof | 诸城市浩天药业有限公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2024206402-A1 | TOPICAL PALA THERAPY FOR CANCER | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-10-03 | — | — | WO | disclosed |
| CN-112779303-B | Method for synthesizing orotic acid by biological enzyme method | 华东理工大学 | 2023-05-02 | — | — | CN | disclosed |
| CN-112779303-A | Method for synthesizing orotic acid by biological enzyme method | 华东理工大学 | 2021-05-11 | — | — | CN | disclosed |
| US-20150238472-A1 | Dimethylarginine Dimethylaminohydrolase Inhibitors and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-08-27 | — | — | US | disclosed |
| US-9011882-B2 | Dimethylarginine dimethylaminohydrolase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-04-21 | — | — | US | disclosed |
| US-20030166615-A1 | Protein kinase and phosphatase inhibitors and methods for designing them | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2003-09-04 | — | — | US | disclosed |
| US-20030148311-A1 | Aspartate carbamyltransferase as herbicidal target | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-07 | — | — | US | disclosed |
| WO-2003035621-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS, METHODS FOR DESIGNING THEM, AND METHODS OF USING THEM | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2003-05-01 | — | — | WO | disclosed |
| EP-1147214-A1 | A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000042213-A1 | A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2000-07-20 | — | — | WO | disclosed |
| EP-0458070-A1 | Cytidine analogue resistance gene DNA and its use | Takeda Chemical Industries, Ltd. (JP) | 1991-11-27 | — | — | EP | disclosed |
| US-5041542-A | Antitumor-anticarcinogenic agents | NUCLEIC ACID RESEARCH INSTITUTE (US) | 1991-08-20 | — | — | US | disclosed |
| US-4873228-A | 2-oxo-4-carboxy-pyrimidines and their use as anti-malaria and anti-cancer agents | THE UNIVERSITY OF MELBOURNE (AU) | 1989-10-10 | — | — | US | disclosed |
| EP-0260057-A2 | 2-Oxo-4-carboxy-pyrimidines | THE UNIVERSITY OF MELBOURNE (AU) | 1988-03-16 | — | — | EP | disclosed |
| US-4550186-A | ANTITUMOR, ANTILIPEMIC, ANTIINFLAMMATORY, AND ANTIARTHRITIC AGENTS | DUKE UNIVERSITY (US) | 1985-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238472-A1 | Dimethylarginine Dimethylaminohydrolase Inhibitors and Methods of Use Thereof | DDAH1, DIMT1, PADI1 | TDP1 191/4885ALDH1A1 563/4885TSHR 3201/4885 |
| US-20030166615-A1 | Protein kinase and phosphatase inhibitors and methods for designing them | PTPN5, PTPN2, PTPN6 | TDP1 1604/4885ALDH1A1 4555/4885TSHR 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.